Medtronic launches InPen

Medtronic has launched InPen, an FDA-cleared smart insulin pen on the market for people on multiple daily injections, integrated with real-time Guardian Connect CGM data. The state-of-the-art system provides insulin dose data, as well as real-time glucose readings.

Users are now able to display all their data in one location and in real-time.

The InPen app will continue to show 180-minute delay details from other currently compatible CGM systems.

Executive Vice President and President of the diabetes business, Medtronic, Sean Salmon, stated: “We’re strongly committed to delivering solutions that make life easier for people living with diabetes. We’re pleased to build on the success of InPen with added real time glucose data which provides a complete picture for users as they look to give themselves the right dose of insulin at the right time. Our successful integration of these devices in just two months following the close of our Companion Medical acquisition is a testament to the close collaboration of our employees and strong passion to serve our customers with better solutions to manage their diabetes.”